Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

• Hui Zheng,
• Eirini Pectasides,
• Mohamed Uduman,
• Charles S Fuchs,
• James M Cleary,
• Adam J Bass,
• Jérémy Augustin,
• Leonie K de Klerk,
• Anuj K Patel,
• Sarah Derks,
• Nihal Raman,
• Fahire G Akarca,
• Nadine J McCleary,
• Douglas A Rubinson,
• Jeffrey W Clark,
• Bridget Fitzpatrick,
• Lauren K Brais,
• Megan E Cavanaugh,
• Amanda J Rode,
• Melissa G Jean,
• Patrick H Lizotte,
• Matthew J Nazzaro,
• Peter C Enzinger

Affiliations

Hui Zheng

Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Eirini Pectasides

8 Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Mohamed Uduman

Aff2 0000 0004 0486 2652grid.420152.0Agenus Inc. 3 Forbes Road 02421 Lexington MA USA

Charles S Fuchs

10 Yale Cancer Center, New Haven, Connecticut, USA

James M Cleary

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Adam J Bass

1 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA

Jérémy Augustin

Institut National de la Santé et de la Recherche Médicale U938, Centre de Recherche de Saint Antoine, Sorbonne Université-Faculté Saint Antoine, Paris, France

Leonie K de Klerk

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Anuj K Patel

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Sarah Derks

Department of Medical Oncology, Amsterdam UMC - Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands

Nihal Raman

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Fahire G Akarca

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nadine J McCleary

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Douglas A Rubinson

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Jeffrey W Clark

Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

Bridget Fitzpatrick

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Lauren K Brais

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Megan E Cavanaugh

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Amanda J Rode

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Melissa G Jean

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Patrick H Lizotte

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Matthew J Nazzaro

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Peter C Enzinger

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA